Daily Cardiology Research Analysis
Analyzed 209 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial (RATE) shows that lower-intensity anticoagulation (low-dose UFH or therapeutic LMWH) is non-inferior to standard-dose UFH for ECMO, suggesting a path to reduce bleeding harm without increasing thrombosis. Proteomic risk stratification (ProteomicDeath23) meaningfully improves mortality prediction beyond MAGGIC and NT-proBNP in heart failure. Mechanistic work in MYBPC3-related hypertrophic cardiomyopathy demonstrates genotype-specific benefits of mavacamten, advancing precision therapeutics.
Research Themes
- Optimizing anticoagulation strategies in ECMO
- Omics-driven risk stratification in heart failure
- Mechanism-based precision therapy in hypertrophic cardiomyopathy
Selected Articles
1. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
In this three-arm, multicenter RCT of ECMO patients, both low-dose UFH and therapeutic LMWH were non-inferior to standard-dose UFH for a composite of severe bleeding, severe thromboembolic events, or 6‑month all-cause mortality. Lower-intensity strategies showed numerically fewer severe bleeding events without excess thromboembolism.
Impact: This is the first adequately powered randomized trial to redefine anticoagulation targets in ECMO, with immediate implications for reducing bleeding without sacrificing thrombotic protection.
Clinical Implications: ECMO protocols can safely consider lower-intensity anticoagulation (low-dose UFH or therapeutic LMWH) to mitigate bleeding risk while maintaining thromboembolic protection, pending local implementation and monitoring.
Key Findings
- Both low-dose UFH and therapeutic LMWH met non-inferiority versus standard-dose UFH for the composite of severe bleeding, severe thromboembolism, or 6‑month mortality.
- Numerically fewer severe bleeding events occurred with low-dose UFH and LMWH compared with standard-dose UFH, without increases in severe thromboembolism.
- At 6 months, mortality rates were similar across arms (50% standard UFH vs 42% low-dose UFH vs 44% LMWH).
Methodological Strengths
- Multicenter randomized non-inferiority design with prespecified composite clinical endpoint and intention-to-treat analysis
- Adequate sample size to test non-inferiority across three arms with clinically relevant outcomes
Limitations
- Open-label design may introduce performance bias
- Conducted in Dutch ICUs; generalizability to other settings and VV vs VA ECMO subgroups warrants confirmation
Future Directions: Confirm findings in broader international cohorts, evaluate patient-centered bleeding outcomes, and refine anticoagulation targets by ECMO mode, indication, and concurrent therapies.
BACKGROUND: In patients receiving extracorporeal membrane oxygenation (ECMO), standard practice is full-dose intravenous unfractionated heparin (UFH) targeting an activated partial thromboplastin time of 2·0-2·5 times baseline to reduce thrombotic risk. This approach can increase bleeding without further reducing thrombosis compared with low-dose UFH. Robust evidence to guide anticoagulation targets is absent because anticoagulation targets in ECMO have never been assessed in a sufficiently powered randomised trial. We aimed to determine whether low-dose UFH or therapeutic low-molecular-weight heparin (LMWH) is non-inferior to standard-dose UFH in patients receiving ECMO. METHODS: In this open-label, three-arm, randomised, non-inferiority trial at seven Dutch intensive care units (ICUs), adults aged 18 years or older supported with veno-venous or veno-arterial ECMO at the ICU without vital indication for full-dose anticoagulation (eg, mechanical mitral valve) were randomly assigned to intravenous standard-dose UFH (activated partial thromboplastin time 2·0-2·5 times baseline), intravenous low-dose UFH (1·5-2·0 times baseline), or therapeutic subcutaneous LMWH. The primary outcome was a composite of severe bleeding during ECMO support, severe thromboembolic complications during ECMO support, or all-cause mortality at 6 months, and was assessed in all randomly assigned patients with deferred informed consent and 6-month follow-up data according to the intention-to-treat principle. Non-inferiority was met if the upper 95% CI limit for the absolute risk difference was less than 7·5 percentage points. This trial is registered at ClinicalTrials.gov (NCT04536272) and the Dutch trial register (NL7976). FINDINGS: Between Oct 22, 2020, and Sept 12, 2024, 330 patients were enrolled: 110 were randomly assigned to standard-dose UFH, 110 to low-dose UFH, and 110 to LMWH. Of 330 enrolled patients, 320 (225 [70%] males, 95 [30%] females; median age 56 years [IQR 45-65]; 255 [80%] White ethnicity) were analysed at 6 months. The composite primary outcome occurred in 87 (81%) of 107 patients with standard-dose UFH, 78 (72%) of 108 with low-dose UFH (absolute risk difference -9·1 percentage points [95% CI -20·3 to 2·1]), and 79 (75%) of 105 with LMWH (-6·1 percentage points [-17·2 to 5·0]), meeting non-inferiority for both interventions. The frequency of severe bleeding was lower with low-dose UFH and LMWH than with standard-dose UFH (63 [58%] patients and 62 [59%] vs 70 [65%]), without excess severe thromboembolic complications (11 [10%] and nine [9%] vs 12 [11%]), although these differences did not reach statistical significance.
2. Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.
Using knock-in mice carrying MYBPC3 p.R502W and complementary human models, the study shows that mavacamten restores sarcomere regulation by counteracting reduced cMyBP‑C–myosin affinity and hypercontractility. Despite preserved cMyBP‑C abundance, pathogenic remodeling occurs and is ameliorated by mavacamten, supporting genotype-directed therapy in MYBPC3 HCM.
Impact: Provides mechanistic, genotype-specific evidence that mavacamten corrects hypercontractility in MYBPC3 HCM, informing precision use beyond MYH7 mutations.
Clinical Implications: Supports genotype-directed mavacamten therapy in MYBPC3 HCM and motivates early intervention trials stratified by mutation class and sarcomeric biophysics.
Key Findings
- Knock-in MYBPC3 p.R502W mice develop pathogenic remodeling despite preserved cMyBP‑C levels and localization.
- R502W reduces cMyBP‑C–myosin affinity leading to sarcomere hypercontractility; mavacamten reverses this by restoring regulatory balance.
- Findings generalize across human and mouse models, supporting mutation-specific therapeutic targeting.
Methodological Strengths
- Genetically precise knock-in model reflecting human MYBPC3 missense pathology
- Cross-species validation combining mouse and human models with mechanistic biophysical insights
Limitations
- Preclinical translational study without randomized clinical outcomes
- Dosing/exposure and long-term remodeling effects require human validation
Future Directions: Prospective genotype-stratified trials of mavacamten in MYBPC3 HCM; define biomarkers of response linked to cMyBP‑C–myosin interaction and contractile reserve.
Mavacamten is a targeted treatment for hypertrophic cardiomyopathy, a disease caused by genetic variants affecting mainly sarcomeric myosin and its regulator cardiac myosin-binding protein C (cMyBP-C, encoded by MYBPC3). Here we generate knock-in mice including missense pathogenic variant cMyBP-C p.R502W, which unlike carriers of cMyBP-C truncations, develop pathogenic myocardial remodeling with preserved cMyBP-C levels and localization. Mechanistically, R502W reduces cMyBP-C-myosin affinity and generates sarcomere hypercontractility due to increased Ca
3. Proteomic markers enhance mortality prediction in heart failure.
In 2,432 HF patients with multi-omics profiling, a 23‑protein score (ProteomicDeath23) was the strongest independent predictor of mortality and improved discrimination beyond MAGGIC and NT‑proBNP (C‑index 0.77). Findings were consistent in UK Biobank validation, while polygenic risk added little.
Impact: Demonstrates clinically actionable improvement in HF mortality prediction using proteomics, supporting integration of molecular phenotyping with standard risk tools.
Clinical Implications: Proteomic panels may refine risk stratification, especially among patients with low NT‑proBNP/MAGGIC risk, informing follow-up intensity, therapy prioritization, and trial enrichment.
Key Findings
- ProteomicDeath23 (23 proteins) was the strongest independent predictor of all-cause mortality (HR per SD 2.23), outperforming NT-proBNP and MAGGIC.
- Combining ProteomicDeath23 with MAGGIC and NT-proBNP achieved the highest discrimination (C-index 0.77); methylation added marginal incremental value and polygenic risk added none.
- Results replicated in an external HF subset of UK Biobank; proteomics stratified risk even among clinically low-risk groups.
Methodological Strengths
- Multi-omics profiling with external validation in UK Biobank
- Direct comparison and incremental value assessment versus established risk tools (MAGGIC, NT-proBNP)
Limitations
- Observational design with potential residual confounding
- Generalizability may be limited by availability of proteomic platforms and cohort characteristics
Future Directions: Prospective clinical utility studies to test proteomic-guided management; evaluate cost-effectiveness and integration into EHR workflows for real-time risk updates.
BACKGROUND AND AIMS: Clinical models incompletely capture the molecular pathways driving heart failure (HF) progression. This study evaluated whether molecular risk stratification provides incremental prognostic information beyond established clinical predictors in patients with HF. METHODS: A total of 2432 patients from the Global Congestive Heart Failure (G-CHF) registry with available genotyping, DNA methylation, and proteomic profiling were analysed. Three molecular scores were assessed: a composite cardiovascular polygenic risk score (PRS) from DNA sequence polymorphisms, a methylation risk score (MRS) derived from epigenome-wide associations, and a 23-protein-based score (ProteomicDeath23). Each score was tested individually and in combination with the clinical Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for mortality prediction. Validation was performed in an HF subset of the UK Biobank (UKB). RESULTS: Over a median follow-up of 3.0 years in G-CHF, 523 patients died from any cause (7.64 per 100 person-years [PY]). In multivariable analyses, ProteomicDeath23 was the strongest independent predictor of all-cause mortality (hazard ratio [HR] per 1 standard deviation, 2.23), outperforming NT-proBNP (HR 2.00), MRSMortality (HR 1.66), PRSmetaCVD (HR 1.10), and the MAGGIC score (HR 1.70). A model combining ProteomicDeath23 with MAGGIC and NT-proBNP achieved the highest discrimination for mortality (C-index, 0.77). Addition of MRSMortality to this proteomic-clinical model resulted in only small improvements in discrimination (ΔC-index, +0.004, P = .0039), while the PRSmetaCVD provided no incremental benefit. Among patients with low NT-proBNP/MAGGIC score, mortality rates increased from 1.71 to 8.12 per 100 PY across ProteomicDeath23 tertiles. Consistent results were observed in the UKB-HF validation cohort.